Other immune checkpoint inhibitors are presently under clinical evaluation in glioblastoma patients, in particular anti-PD-1 (nivolumab, pembrolizumab) and anti-PD-L1 (MEDI4736) antibodies. The gene discussed is CD274; the disease is glioblastoma.